



Ref: Syn/CS/SE/Reg 30/2025-26/Dec/04

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India

T +91 80 6891 9191

CIN: L85110KA1993PLC014937

www.syngeneintl.com

December 11, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Intimation of Webinar on Clinical Trials Market

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation of Webinar on Clinical Trials Market by Dr. Mrinal Kammili (Head of Translational & Clinical Research) for Analysts and Investors to be held on Wednesday, December 17, 2025.

The above-mentioned information will also be available on the website of the Company www.syngeneintl.com.

Request to kindly take this intimation on record.

Thanking you,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Chethan Yogesh
Company Secretary & Compliance Officer

Webinar on Clinical Trials Market

Webinar on Clinical Trials Market – by Dr. Mrinal Kammili

At 1:30 PM IST on 17th December 2025

The management team of Syngene International Limited (“Syngene”) is pleased to invite you to a **Webinar on Clinical Trials Market, 17th December 2025 at 1:30 pm IST.**

Dr. Mrinal Kammili, our in-house Clinical Research expert, will share insights on Clinical Trials research business, industry and Syngene offerings in the Translation and Clinical Research (T&CR) segment followed by an interactive Question & Answer session.

This webinar is meant for providing more clarity on Clinical trials industry and Syngene offerings and not for discussion around Syngene specific financials. Mr. Mrinal Kammili - Head, Translational & Clinical Research and other members of the senior management team will represent Syngene on the conference call.

Details of the conference call are as under:

Date:	Wednesday, 17th December 2025
Time:	1:30 pm to 2:30 pm IST
Dial-in Numbers*	
Primary Number	+91 22 6280 1279 / 91 22 7115 8180
International Numbers	USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448 Australia – 0080014243444
Pre-registration Facility (Diamond Pass™ link)	Step 1: Please mandatorily RSVP at Shubham.jain@syngeneintl.com by 15 Dec to reserve your participation in the webinar Step 2: Pre-register here . You will receive a passcode and a pin for the call on the registered email address.

Webinar on Clinical Trials Market

	Step 3: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call.
Participants can also join the webcast with the link:	https://links.ccwebcast.com/?EventId=SNG171225

About Syngene

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ Mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit [Syngene ESG Report](#).

For further information, please contact:

Nandini Agarwal / Shubham Jain

M:+ 91 7838382527 / +91 6377651994

E: Nandini.agarwal@syngeneintl.com

E: shubham.jain@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.